Does kisqali work for breast cancer?

See the DrugPatentWatch profile for kisqali

Does Kisqali work for breast cancer?

Kisqali is approved to treat HR-positive, HER2-negative advanced or metastatic breast cancer. It is combined with an aromatase inhibitor for postmenopausal women or with fulvestrant for those whose disease has progressed after endocrine therapy.

How effective is Kisqali in clinical trials?

In the MONALEESA-2 trial, Kisqali plus letrozole extended median progression-free survival to 25.3 months versus 16 months with letrozole alone. The MONALEESA-3 trial showed Kisqali plus fulvestrant improved progression-free survival to 20.5 months versus 12.8 months with fulvestrant alone. MONALEESA-7, which studied premenopausal women, reported 27.5 months versus 13.8 months.

What overall survival data exist?

Updated analyses from MONALEESA-2 and MONALEESA-7 showed Kisqali reduced the risk of death by 24% and 29%, respectively. MONALEESA-3 reported a 28% reduction in death risk.

Can Kisqali be used earlier in treatment?

Kisqali is approved for first-line use in postmenopausal women with HR-positive, HER2-negative metastatic breast cancer and for patients who progressed on prior endocrine therapy. It is not indicated for early-stage disease.

Are there differences by menopausal status?

The drug is approved for both pre- and postmenopausal women when combined with appropriate endocrine therapy. MONALEESA-7 specifically confirmed benefit in premenopausal women receiving ovarian suppression plus Kisqali and an aromatase inhibitor.

What side effects matter most to patients?

Common side effects include low white blood cell counts, nausea, fatigue, diarrhea, and hair thinning. QT-interval prolongation is a serious risk that requires ECG monitoring. Dose reductions or interruptions occur in about half of patients due to side effects.

How long do patients typically stay on Kisqali?

Treatment continues until disease progression or unacceptable toxicity. Median duration in trials ranged from 12 to 20 months depending on the combination partner and patient population.

When does Kisqali's patent expire?

Novartis holds composition-of-matter protection until 2031 in the United States. DrugPatentWatch.com tracks patent and exclusivity timelines.

Are biosimilars or generics expected soon?

No generic versions are available. The first generic entry is not expected before the 2031 patent expiry.

Who makes Kisqali?

Kisqali is manufactured by Novartis.